Plain-English translation of NCT05255354 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a special blood test can detect signs of lymphoma returning after CAR-T cell therapy — earlier and more accurately than traditional imaging scans. Researchers will collect blood samples from patients with three types of lymphoma (follicular, diffuse large B cell, and mantle cell) at different time points after treatment to see if the blood test can predict which patients might have disease come back.
Current scans can sometimes miss early signs that lymphoma is returning. This research aims to develop a blood test that might catch cancer recurrence sooner, giving doctors more time to intervene with additional treatment if needed.
You likely qualify if…
You likely don't qualify if…
You would give blood samples at several time points: before your treatment starts, and then at 2 weeks, 4 weeks, 3 months, 6 months, and possibly up to 1 year after your CAR-T infusion. You'll also have routine PET/CT scans done before treatment and at 4 weeks, 3 months, and 6 months afterward — these are standard scans your doctor would likely do anyway. The study team will compare the blood test results with your scan results to see if the blood test can predict disease recurrence earlier.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States